Literature DB >> 16403067

Atrial natriuretic peptide has dose-dependent, autonomically mediated effects on atrial refractoriness and repolarization in anesthetized dogs.

Bruce S Stambler1, Gary B Guo.   

Abstract

INTRODUCTION: Atrial natriuretic peptide (ANP) may alter electrophysiological properties of the heart and possibly have a role in arrhythmogenesis. However, previous studies have yielded conflicting results and have not fully considered whether ANP's cardiac electrophysiological effects are mediated via direct actions and/or indirectly via the autonomic nervous system. This study's aim was to establish whether ANP infused at pathophysiological and pharmacological doses has significant in vivo cardiac electrophysiological effects and to determine whether these effects are directly or autonomically mediated. METHODS AND
RESULTS: Electrophysiologic and hemodynamic effects of ANP infusion (human ANP at 15-600 ng/kg per minute) were examined in chloralose-anesthetized dogs under conditions of varying autonomic blockade. In autonomically intact dogs (n = 12), low-dose ANP (15 ng/kg per minute) shortened atrial effective refractory period (ERP) (P < 0.001) and monophasic action potential duration (MAPD90) (P < 0.05) at 600, 500, and 400 msec atrial paced cycle lengths and reduced right atrial pressure (P < 0.05) but did not alter mean arterial pressure. After either combined vagal and beta-adrenergic blockade (vagotomy plus atropine plus propranolol, n = 7) or selective vagal blockade (n = 9), low-dose ANP no longer altered atrial ERP or MAPD90. Higher ANP doses (150 and 600 ng/kg per minute) decreased mean arterial and right atrial pressures (P < 0.001) but did not alter atrial ERP, MAPD90, or other electrophysiological parameters including atrial fibrillation threshold, ventricular ERP, and MAPD90.
CONCLUSION: ANP has dose-dependent, autonomically mediated effects on atrial refractoriness and repolarization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16403067     DOI: 10.1111/j.1540-8167.2005.00259.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

Review 1.  Monogenic atrial fibrillation as pathophysiological paradigms.

Authors:  Saagar Mahida; Steven A Lubitz; Michiel Rienstra; David J Milan; Patrick T Ellinor
Journal:  Cardiovasc Res       Date:  2010-11-30       Impact factor: 10.787

2.  A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.

Authors:  Deborah M Dickey; Andrea R Yoder; Lincoln R Potter
Journal:  J Biol Chem       Date:  2009-05-19       Impact factor: 5.157

3.  Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.

Authors:  Denice M Hodgson-Zingman; Margaret L Karst; Leonid V Zingman; Denise M Heublein; Dawood Darbar; Kathleen J Herron; Jeffrey D Ballew; Mariza de Andrade; John C Burnett; Timothy M Olson
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

4.  Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation.

Authors:  Robert L Abraham; Tao Yang; Marcia Blair; Dan M Roden; Dawood Darbar
Journal:  J Mol Cell Cardiol       Date:  2009-07-30       Impact factor: 5.000

Review 5.  Inherited and Acquired Rhythm Disturbances in Sick Sinus Syndrome, Brugada Syndrome, and Atrial Fibrillation: Lessons from Preclinical Modeling.

Authors:  Laura Iop; Sabino Iliceto; Giovanni Civieri; Francesco Tona
Journal:  Cells       Date:  2021-11-15       Impact factor: 6.600

6.  Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing.

Authors:  Xule Wang; Qingyan Zhao; He Huang; Yanhong Tang; Jinping Xiao; Zixuan Dai; Shengbo Yu; Congxin Huang
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

Review 7.  Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways.

Authors:  Muhammad A Balouch; Matthew J Kolek; Dawood Darbar
Journal:  Glob Cardiol Sci Pract       Date:  2014-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.